Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Britannia Life SciencesBLSIF Equity-to-Asset is 0.87 as of Mar. 2026, which is 335% above its 10-year median of 0.20. The stock has 5 warning signs investors should review. Among 1,414 Biotechnology companies, Britannia Life Sciences ranks better than 77.16% on this metric.
Britannia Life Sciences (OTCPK:BLSIF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Britannia Life Sciences Equity-to-Asset Related Terms
Britannia Life Sciences Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLSIF vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Britannia Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Britannia Life Sciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Britannia Life Sciences's Equity-to-Asset falls into.
Britannia Life Sciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Britannia Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Britannia Life Sciences (BLSIF) has a Equity-to-Asset of 0.87 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Britannia Life Sciences and its competitors. This is 335% above median its historical median of 0.20. According to the industry distribution chart, Britannia Life Sciences ranks #323 out of 1414 companies in the Biotechnology industry, placing it in the top 22.8%.
Is Britannia Life Sciences' Equity-to-Asset too high?
Britannia Life Sciences' current Equity-to-Asset of 0.87 is 335% above median its 10-year median of 0.20. The Biotechnology industry median Equity-to-Asset is 0.69. Britannia Life Sciences' value of 0.87 is 26.1% above this industry median. Based on the distribution chart, Britannia Life Sciences ranks #323 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Britannia Life Sciences' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #323 out of 1414 companies for Equity-to-Asset. This places Britannia Life Sciences in the top 23% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.69. Britannia Life Sciences' value of 0.87 is 26.1% above this benchmark. While the company's 10-year median is 0.20 vs. the industry median of 0.69, Britannia Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Britannia Life Sciences's current Equity-to-Asset of 0.87 is 26.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Britannia Life Sciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Britannia Life Sciences's current Equity-to-Asset is 0.87, which is 335% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (BLSIF) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is 335% above median its 10-year median of 0.20 and 26.1% above the Biotechnology industry median of 0.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Britannia Life Sciences (BLSIF), the current Equity-to-Asset is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSIF has been successfully added to your 
